|
Three Pulmatrix PUR118 clinical studies on COPD, asthma to be presented at …
News-Medical.net Pulmatrix, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, announced today that three posters on its lead iCALM™ therapeutic, the first treatment developed utilizing its iSPERSE™ inhaled drug platform, will be … |
View full post on asthma – Google News